NuCana plc remains a clinical-stage player specializing in oncology therapeutics, with its pipeline centered on NUC-7738 and NUC-3373. The company posted a substantial net loss of £29.4 million in 2025, worsening from prior years, while maintaining a healthy cash position of £24.3 million at year-end. Its value proposition hinges on proprietary drug candidates protected by issued patents, with key development milestones expected from ongoing trials in PD-1 inhibitor-resistant melanoma and other indications. Capital structure improvements and leadership appointments seek to stabilize operations amid the uncertainty typical for pre-commercial biopharmaceutical companies.